Online inquiry

IVTScrip™ mRNA-Anti-IGHE, 47H4(Cap 0, 2-Thio-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ509MR)

This product GTTS-WQ509MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets IGHE gene. The antibody can be applied in Urticaria research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Humanized
RefSeq NC_000014.9
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3497
UniProt ID P01854
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IGHE, 47H4(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) (GTTS-WQ509MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ8902MR IVTScrip™ mRNA-Anti-IGHE, IGE25(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA IGE25
GTTS-WQ9756MR IVTScrip™ mRNA-Anti-PDCD1, JS001(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA JS001
GTTS-WQ5899MR IVTScrip™ mRNA-Anti-IL31RA, CIM 331(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA CIM 331
GTTS-WQ7538MR IVTScrip™ mRNA-Anti-CLDN18, GC-182(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA GC-182
GTTS-WQ9368MR IVTScrip™ mRNA-Anti-PDCD1, INCMGA-00012(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA INCMGA-00012
GTTS-WQ11651MR IVTScrip™ mRNA-Anti-HA, MHAA4549A(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MHAA4549A
GTTS-WQ1824MR IVTScrip™ mRNA-Anti-CFD, AFD Anti-fD(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA AFD Anti-fD
GTTS-WQ12599MR IVTScrip™ mRNA-Anti-F11, NVS250519(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA NVS250519
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW